Did Spero Therapeutics provide any updated revenue or earnings guidance for the remainder of 2025, and what is the market's reaction to that guidance?

Guidance:

In the August 12, 2025 release Spero Therapeutics (NASDAQ: SPRO) disclosed its Q2 2025 operating results and a broader business update, but the filing did not contain any revised revenue or earnings outlook for the balance of 2025. The company reiterated its focus on advancing its pipeline of rare‑disease and MDR‑infection programs, but it stopped short of issuing new top‑line guidance or earnings forecasts beyond the prior expectations.

Market reaction:

Because the update offered no fresh forward‑looking numbers, the market treated the news as a “status‑quo” event. SPRO’s shares opened flat to slightly lower on the Nasdaq, slipping roughly 1‑2 % in the first half‑day as investors digested the lack of concrete guidance and the continued uncertainty around the timing of pivotal trial read‑outs and potential product launches. The modest sell‑off reflects a typical reaction when a clinical‑stage biotech fails to lift the “guidance‑deficit” that many growth‑oriented investors look for in earnings releases.

Trading implications:

- Short‑term: The modest downside bias suggests a short‑term sell‑or‑hold stance unless the price breaks below the recent low‑volume support around $4.80, which could trigger a deeper correction on broader risk‑off sentiment.

- Medium‑term: With no updated guidance, the stock remains heavily dependent on upcoming clinical milestones (e.g., Phase III read‑outs, FDA interactions). A positive data release later in the year would be a catalyst for a buy‑on‑dip opportunity.

- Risk management: Keep a tight stop just below the current support zone (≈ $4.70) and monitor volume‑weighted average price (VWAP) for any signs of sustained buying pressure. Until the company provides a clearer revenue/earnings outlook, the trade‑off leans toward a defensive posture rather than a directional long play.